Telomir Pharmaceuticals, Inc. (TELO)
NASDAQ: TELO · IEX Real-Time Price · USD
6.54
+0.52 (8.64%)
At close: May 9, 2024, 4:00 PM
6.60
+0.06 (0.92%)
Pre-market: May 10, 2024, 4:39 AM EDT
Company Description
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells.
The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.
The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022.
Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
Telomir Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2021 |
| IPO Date | Feb 9, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Dr. Christopher Chapman, Jr. |
Contact Details
Address: 900 West Platt Street, Suite 200 Tampa, Florida 33606 United States | |
| Phone | (813) 864-2562 |
| Website | telomirpharma.com |
Stock Details
| Ticker Symbol | TELO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $7.00 |
| CIK Code | 0001971532 |
| Employer ID | 87-2606031 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher C. Chapman Jr., M.D. | Co-Founder, Chairman and Chief Executive Officer |
| Nathen Fuentes CPA | Chief Financial Officer, Treasurer, and Secretary |
| Christos Nicholoudis Esq. | General Counsel and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2024 | 8-K | Current Report |
| Apr 12, 2024 | 8-K | Current Report |
| Mar 29, 2024 | 10-K | Annual Report |
| Feb 13, 2024 | 8-K | Current Report |
| Feb 12, 2024 | 424B4 | Prospectus |
| Feb 12, 2024 | 424B1 | Filing |
| Feb 8, 2024 | EFFECT | Notice of Effectiveness |
| Feb 8, 2024 | CERT | Certification by an exchange approving securities for listing |
| Feb 6, 2024 | 8-A12B | Registration of securities |
| Jan 3, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |